Skip to content

José Augusto Silva Reis

6 papers in the library · 16 citations · publishing 0-2026

Papers

Sort Most recent Most cited

Classic psychedelics and personality: An updated systematic review.

Journal of psychopharmacology (Oxford, England) May 31, 2026 Anna Beatriz Vicentini, Caio César De Paula, José Augusto Silva Reis et al.

The impact of classic psychedelics (5-HT2A receptor agonists) on personality traits has been studied for decades, and it has been hypothesized that the mechanisms underlying these changes are linked to agonism at cortical serotonergic 5-HT2A receptors. However, research results are contradictory. Therefore, the present paper aims to systematically evaluate the effects of psychedelics on...

Predicting drug–drug interactions between ayahuasca alkaloids and SSRIs using physiologically based pharmacokinetic modeling

Frontiers in Molecular Biosciences February 18, 2026 Gabriella de Souza Gomes Ribeiro, Beatriz Aparecida Passos Bismara Paranhos, Fabiane Dörr et al. 1 citation

The findings suggest a clinically relevant interaction between ayahuasca and SSRIs, as even modest increases in DMT exposure may intensify serotonergic effects in individuals receiving antidepressant therapy. This study provides a mechanistic and quantitative framework for assessing interaction risks between ayahuasca alkaloids and SSRIs, supporting clinical decision-making and harm-reduction...

Feasibility, safety and preliminary effects of ibogaine in patients with moderate and severe alcohol use disorder: a pilot, open-label study

Trends in Psychiatry and Psychotherapy 2026 Juliana Mendes Rocha, Renan Massanobu Maekawa, José Augusto Silva Reis et al.

INTRODUCTION: Ibogaine is a natural hallucinogen with emerging evidence for treating substance use disorders. However, its cardiovascular effects are not fully known, and most clinical data focus on opioid dependence, with limited data for Alcohol Use Disorder (AUD). This study assessed the feasibility, safety, and preliminary effects of ibogaine in patients with AUD. METHOD: In this...

Guidelines for Establishing Safety in Ayahuasca and Ibogaine Administration in Clinical Settings

Psychoactives December 11, 2023 Juliana Mendes Rocha, José Augusto Silva Reis, Giordano Novak Rossi et al. 3 citations

As the research field with psychedelic substances grows, it is expected to encompass a more extensive cohort of individuals presenting a spectrum of medical conditions, comorbidities, and unique physiological traits, thereby increasing the likelihood of potential adverse events. Furthermore, it is worth noting that there is a scarcity of the specialized literature regarding procedures to ensure...

Subjective Effects of a Single Dose of Ayahuasca among College Students with Harmful Alcohol Use: Qualitative Analysis of Participant Accounts

Psychoactives November 17, 2023 Anna Beatriz Vicentini, Lucas Silva Rodrigues, Giordano Novak Rossi et al. 4 citations

Alcohol is the recreational drug most frequently consumed, and its high frequency of use can lead to worsening social, psychological, and domestic issues. The age group most susceptible to alcohol dependence is 18- to 24-year-old youths, demanding interventional tools to target early involvement risks. Ayahuasca seems to be a promising therapeutic tool since evidence suggests it presents...

Effects of a Single Dose of Ayahuasca in College Students With Harmful Alcohol Use: A Single-blind, Feasibility, Proof-of-Concept Trial.

Journal of Clinical Psychopharmacology Lucas Silva Rodrigues, José Augusto Silva Reis, Giordano Novak Rossi et al. 8 citations

Ayahuasca is a South American plant hallucinogen rich in the psychedelic N,N-dimethyltryptamine and β-carbolines (mainly harmine). Preclinical and observational studies suggest that ayahuasca exerts beneficial effects in substance use disorders, but these potentials were never assessed in a clinical trial. Single-center, single-blind, feasibility, proof-of-concept study, assessing the effects...